Table 4.
Results of meta-analysis.
| Outcome | Effect Estimate | 95% CI | p-Value | Prediction Interval | I2 |
|---|---|---|---|---|---|
| Recurrence (non-randomised studies) | |||||
| 1-year (RR) | 1.01 | 0.78–1.31 | 0.93 | - | 0% |
| 3-year (RR) | 1.00 | 0.85–1.18 | 0.97 | - | 0% |
| 5-year (RR) | 1.04 | 0.87–1.25 | 0.67 | - | 21% |
| Time-to-event (HR) | 1.18 | 0.78–1.79 | 0.32 | 0.42–3.35 | 9% |
| Overall survival (randomised studies) | |||||
| 1-year (RR) | 1.20 | 0.55–2.60 | 0.65 | - | 0% |
| 3-year (RR) | 1.09 | 0,70–1.70 | 0.69 | - | 0% |
| 5-year (RR) | 1.64 | 1.00–2.71 | 0.05 | - | 0% |
| Time-to-event (HR) | 1.46 | 0.61–3.46 | 0.20 | 0.07–30.4 | 0% |
| Overall survival (non-randomised studies) | |||||
| 1-year (RR) | 0.70 * | 0.51–0.97 | 0.03 | - | 29% |
| 3-year (RR) | 0.89 | 0.71–1.13 | 0.34 | - | 68% |
| 5-year (RR) | 1.02 | 0.84–1.25 | 0.81 | - | 80% |
| Time-to-event (HR) | 0.98 | 0.75–1.27 | 0.86 | 0.44–2.19 | 60% |
| Disease-free survival (randomised studies) | |||||
| 1-year (RR) | 1.34 | 0.37–4.83 | 0.65 | - | 14% |
| 3-year (RR) | 1.31 | 0.74–2.31 | 0.35 | - | 0% |
| 5-year (RR) | 1.54 | 0.94–2.53 | 0.09 | - | 0% |
| Disease-free survival (non-randomised studies) | |||||
| 1-year (RR) | 0.77 * | 0.60–0.97 | 0.03 | - | 0% |
| 3-year (RR) | 1.08 | 0.78–1.51 | 0.64 | - | 79% |
| 5-year (RR) | 1.11 | 0.74–1.67 | 0.61 | - | 93% |
| Time-to-event (HR) | 1.03 | 0.65–1.62 | 0.88 | 0.31–3.36 | 84% |
Abbreviations: RR = risk ratio; HR = hazard ratio; CI = confidence interval. * Significant result.